IGF2: The Achilles' heel of p53‐deficiency?

[...]approach is, however, only applicable to tumours expressing wild‐type p53. Because alteration of p53 is so frequent in cancer, identification of synthetic lethal partners of p53 should lead to conceptually simple and attractive approaches to selective targeting of cancer cells (Kaelin, 2005). [...]Haley and colleagues also assessed the impact of Igf2 inactivation on tumour development. [...]IGF2 targeting should be explored as a putative therapeutic avenue for reactivation of p53 tumour suppressor function in cancers with IGF2 LOI.